Abstract
Background: Acquired immunodeficiency syndrome (AIDS) and cancer treatment have been a major task for research scientists and pharmaceutical industry for the last many years. Seeking to the development, many promising chemical entities especially five-membered heterocyclic rings like oxadiazole have revealed good anticancer and anti HIV activities. The current review enlists some recently developed anti-HIV and anti-cancer oxadiazole moieties.
Methods: on the basis of structural modification for the syntheses of new oxadiazole analogs, the new anti-HIV and anti-cancer agents have been summarized, which can improve treatment of AIDs and cancer.
Results: The oxadiazole ring is more potent in comparison to some other heterocyclic rings (five and six membered) towards anti-HIV and anti-cancer activities. The important mechanisms involved for anti HIV and anticancer activity are mainly inhibition of enzymes like protease, HIV-integrase, telomerase, histone deacetylase, methionine amino peptidase, thymidylate synthase and focal adhesion kinase and inhibition of some growth factors.
Conclusion: By reviving the past literature about 50 most potent oxadiazole derivatives, depending upon activity and structural modifications, have been selected as potent anti-HIV, and anti-cancer agents. Thus, oxadiazole seems to be a ‘privileged structure’ for further screening and syntheses of the new drug analogs against life threatening HIV and cancer like diseases.
Keywords: Oxadiazole, anti-HIV, cancer, heterocyclic compounds, drug discovery, HIV–integrase inhibitor raltegravir, antiproliferative activity.
Graphical Abstract
[1]
Kumar, D.; Judge, V.; Narang, R.; Sangwan, S.; De Clercq, E.; Balzarini, J.; Narasimhan, B. Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation. Eur. J. Med. Chem., 2010, 45(7), 2806-2816.
[2]
De Clercq, E. Highlights in the development of new antiviral agents. Mini Rev. Med. Chem., 2002, 2(2), 163-175.
[3]
Kumar, D.; Kumar, V.; Mundlia, J.; Pradhan, D.; Malik, S. Thiazolidin-4-one derivatives as central nervous system potential agents. Cent. Nerv. Syst. Agents Med. Chem., 2015, 15, 23-27.
[4]
Liu, Z.; Chen, W.; Zhan, P.; Clercq, D.E.; Pannecouque, C.; Design, X.L. Synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. Eur. J. Med. Chem., 2014, 87, 52-62.
[5]
Patel, M.B.; Modi, N.R.; Raval, J.P.; Menon, S.K. Calix[4]arene based 1,3,4-oxadiazole and thiadiazole derivatives: design, synthesis, and biological evaluation. Org. Biomol. Chem., 2012, 10(9), 1785-1794.
[6]
Benmansour, F.; Eydoux, C.; Querat, G.; de Lamballerie, X.; Canard, B.; Alvarez, K.; Guillemot, J.C.; Barral, K. Novel 2-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,3,4-oxadiazole and 3-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,2,4-oxadiazole derivatives as dengue virus inhibitors targeting NS5 polymerase. Eur. J. Med. Chem., 2016, 109, 146-156.
[7]
Thomas, S.J.; Endy, T.P. Current issues in dengue vaccination. Curr. Opin. Infect. Dis., 2013, 26(5), 429-434.
[8]
Savarino, A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin. Investig. Drugs, 2006, 15(12), 1507-1522.
[10]
Kumar, D.; Kapoor, A.; Kumar, P.; Thangadurai, A.; Narasimhan, B. Synthesis, antimicrobial evaluation and QSAR studies of 3-ethoxy-4-hydroxybenzylidene/4-nitrobenzylidene hydrazides. Chin. Chem. Lett., 2011, 22(11), 1293-1296.
[11]
Mickevičius, V.; Vaickelionienė, R.; Sapijanskaitė, B. Synthesis of substituted 1,3,4- oxadiazole derivatives. Chem. Heterocycl. Compd., 2009, 45, 215-218.
[12]
El Sadek, M.M.; Hassan, S.Y.; Abdelwahab, H.E.; Yacout, G.A. Synthesis and bioassay of a new class of furanyl-1,3,4-oxadiazole derivatives. Molecules, 2013, 18(7), 8550-8562.
[13]
Holla, B.S.; Poojary, K.N.; Bhat, K.S.; Ashok, M.; Poojary, B. Synthesis and anticancer activity studies on some 2-chloro-1,4-bis-(5- substituted-1,3,4-oxadiazol-2-ylmethyleneoxy) phenylene derivatives. Org. Med. Chem., 2005, 44(8), 1669-1673.
[14]
Ouyang, X.; Piatnitski, E.L.; Pattaropong, V.; Chen, X.; He, H.Y.; Kiselyov, A.S.; Velankar, A.; Kawakami, J.; Labelle, M.; Smith, L., II; Lohman, J.; Lee, S.P.; Malikzay, A.; Fleming, J.; Gerlak, J.; Wang, Y.; Rosler, R.L.; Zhou, K.; Mitelman, S.; Camara, M.; Surguladze, D.; Doody, J.F.; Tuma, M.C. Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines. Bioorg. Med. Chem. Lett., 2006, 16(5), 1191-1196.
[15]
Steigbigel, R.T.; Cooper, D.A.; Kumar, P.N.; Eron, J.E.; Schechter, M.; Markowitz, M.; Loutfy, M.R.; Lennox, J.L.; Gatell, J.M.; Rockstroh, J.K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Zhao, J.; Chen, J.; Ryan, D.M.; Rhodes, R.R.; Killar, J.A.; Gilde, L.R.; Strohmaier, K.M.; Meibohm, A.R.; Miller, M.D.; Hazuda, D.J.; Nessly, M.L.; DiNubile, M.J.; Isaacs, R.D.; Nguyen, B.Y.; Teppler, H. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med., 2008, 359(4), 339-354.
[16]
Zareef, M.; Iqbal, R.; Al-Masoudi, N.A.; Zaidi, J.H.; Arfan, M.; Shahzad, S. Synthesis, AntiHIV, and Antifungal Activity of New Benzensulfonamides Bearing the 2, 5-Disubstituted-1, 3, 4-Oxadiazole Moiety. Phosphorus Sulfur Silicon Relat. Elem., 2007, 182(2), 281-298.
[17]
Iqbal, R.; Zareef, M.; Ahmed, S.; Zaidi, J.H.; Arfan, M. Shafiqueb. M.; Al-Masoudic, N. A. Synthesis, Antimicrobial and Anti-HIV Activity of Some Novel Benzenesulfonamides Bearing 2, 5-Disubstituted-1, 3, 4-oxadiazole Moiety. J. Chin. Chem. Soc. (Taipei), 2006, 53, 689-696.
[18]
Jorgensen, W.L. Computer-aided discovery of anti-HIV agents. Bioorg. Med. Chem., 2016, 24(20), 4768-4778.
[19]
Abdel-Aziz, M. Abuo-Rahma, Gel-D.; Hassan, A.A. Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities. Eur. J. Med. Chem., 2009, 44(9), 3480-3487.
[20]
Almasirad, A.; Tabatabai, S.A.; Faizi, M.; Kebriaeezadeh, A.; Mehrabi, N.; Dalvandi, A.; Shafiee, A. Synthesis and anticonvulsant activity of new 2-substituted-5- [2-(2-fluorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles. Bioorg. Med. Chem. Lett., 2004, 14(24), 6057-6059.
[21]
Manjunatha, K.; Poojary, B.; Lobo, P.L.; Fernandes, J.; Kumari, N.S. Synthesis and biological evaluation of some 1,3,4-oxadiazole derivatives. Eur. J. Med. Chem., 2010, 45(11), 5225-5233.
[22]
Shailaja, M.; Anitha, M.; Manjula, A.; Rao, B.V. Synthesis and biological activity of novel 2,5-disubstituted-l,3,4- oxadiazoles. Indian J. Chem., 2010, 49(8), 1088-1097.
[23]
Mulwad, V.V.; Chaskar, A.C. Synthesis and antibacterial activity of new oxadiazolo[1,3,5]-triazine, 1,2,4 triazolo and thiadiazolo 1,3,4 oxadiazole derivatives. ChemInform, 2006, 45(7), 1710-1715.
[24]
Ansari, K.F.; Lal, C. Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents. Eur. J. Med. Chem., 2009, 44(5), 2294-2299.
[25]
Dewangan, D.; Pandey, A.; Sivakumar, T.; Rajavel, R.; Dubey, R.D. Synthesis of some Novel 2, 5-Disubstituted 1, 3, 4-oxadiazole and its analgesic, anti-inflammatory, anti-bacterial and anti-tubercular activity. Int. J. Chemtech Res., 2010, 3(3), 1397-1412.
[26]
Bhandari, S.V.; Bothara, K.G.; Raut, M.K.; Patil, A.A.; Sarkate, A.P.; Mokale, V.J. Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives. Bioorg. Med. Chem., 2008, 16(4), 1822-1831.
[27]
Ali, M.A.; Shaharyar, M. Oxadiazole mannich bases: synthesis and antimycobacterial activity. Bioorg. Med. Chem. Lett., 2007, 17(12), 3314-3316.
[28]
Ogata, M.; Atobe, H.; Kushida, H.; Yamamoto, K. In vitro sensitivity of mycoplasmas isolated from various animals and sewage to antibiotics and nitrofurans. J. Antibiot. (Tokyo), 1971, 24(7), 443-451.
[29]
Vardan, S.; Smulyan, H.; Mookherjee, S.; Eich, R. Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables. Clin. Pharmacol. Ther., 1983, 34(3), 290-296.
[30]
Schlecker, R.; Thieme, P.C. The synthesis of antihypertensive 3-(1, 3, 4-oxadiazol-2-yl) phenoxypropanolamines. Tetrahedron, 1988, 44(11), 3289-3294.
[31]
Patel, M.B.; Modi, N.R.; Raval, J.P.; Menon, S.K. Calix[4]arene based 1,3,4-oxadiazole and thiadiazole derivatives: design, synthesis, and biological evaluation. Org. Biomol. Chem., 2012, 10(9), 1785-1794.
[32]
Shaik, B.; Agrawal, V.; Gupta, S.P.; Menon, U. Quantitative structure-activity relationship and docking studies on a series of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Lett. Drug Des. Discov., 2017, 4(1), 10-27.
[33]
Tan, T.M.C.; Chen, Y.; Kong, K.H.; Bai, J.; Li, Y.; Lim, S.G.; Ang, T.H.; Lam, Y. Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents. Antiviral Res., 2006, 71(1), 7-14.
[34]
Abu-Zaied, M.A.; El-Telbani, E.M.; Elgemeie, G.H.; Nawwar, G.A.M. Synthesis and in vitro anti-tumor activity of new oxadiazole thioglycosides. Eur. J. Med. Chem., 2011, 46(1), 229-235.
[35]
Liu, K.; Lu, H.; Hou, L.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B.T.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem., 2008, 51(24), 7843-7854.
[36]
Zarghi, A.; Hajimahdi, Z. Substituted oxadiazoles: a patent review (2010 - 2012). Expert Opin. Ther. Pat., 2013, 23(9), 1209-1232.
[37]
Kaur, H.; Saini, S.; Peer, S.; Singh, J. Current therapies and novel targets in treatment of breast cancer. Sys Rev Pharm, 2010, 1(1), 40-49.
[38]
Bajaj, S.; Asati, V.; Singh, J.; Roy, P.P. 1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. Eur. J. Med. Chem., 2015, 97(5), 124-141. 1,3,4- Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents
[39]
Mochona, B.; Qi, X.; Euynni, S.; Sikazwi, D.; Mateeva, N.; Soliman, K.F. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg. Med. Chem. Lett., 2016, 26(12), 2847-2851.
[40]
Che, Z.; Liu, S.; Tian, Y.; Hu, Z.; Chen, Y.; Chen, G. Design and synthesis of novel N-Arylsulfonyl-3-(2-yl-ethanone)-6-methylindole derivatives as inhibitors of HIV-1 replication. Pharmaceuticals (Basel), 2015, 8(2), 221-229.
[41]
Sun, J.; Li, M.; Quin, S.S.; Guo, F.J.; Dang, X.F.; Wang, X.M.; Xue, Y.R.; Zhu, H.L. Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors. Bioorg. Med. Chem. Lett., 2013, 23(10), 2876-2879.
[42]
Manal, M.; Chandrasekar, M.J.N.; Gomathi Priya, J.; Nanjan, M.J. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg. Chem., 2016, 67, 18-42.
[43]
Sakamoto, T.; Cullen, M.D.; Hartman, T.L.; Watson, K.M.; Buckheit, R.W.; Pannecouque, C.; De Clercq, E.; Cushman, M. Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J. Med. Chem., 2007, 50(14), 3314-3321.
[44]
El-Sayed, W.A.; El-Essawy, F.A.; Ali, O.M.; Nasr, B.S.; Abdalla, M.M.; Abdel-Rahman, A.A. Anti-HIV activity of new substituted 1,3,4-oxadiazole derivatives and their acyclic nucleoside analogues. Z. Natforsch. C J. Biosci., 2009, 64(11-12), 773-778.
[45]
Wang, Z.; Wang, M.; Yao, X.; Li, Y.; Qiao, W.; Geng, Y.; Liu, Y.; Wang, Q. Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors. Eur. J. Med. Chem., 2012, 50, 361-369.
[46]
El-Emam, A.A.; Al-Deeb, O.A.; Al-Omar, M.; Lehmann, J. Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem., 2004, 12(19), 5107-5113.
[47]
Iqbal, R.; Zareef, M.; Ahmed, S.; Zaidi, J.H.; Arfan, M.; Shafique, M.; Al-masoudi, N.A. Synthesis, antimicrobial and anti-HIV activity of some novel benzenesulfonamides bearing 2,5-disubstituted-1,3,4-oxadiazole moiety. J. Chin. Chem. Soc. (Taipei), 2006, 53, 689-696.
[48]
Kim, R.M.; Rouse, E.A.; Chapman, K.T.; Schleif, W.A.; Olsen, D.B.; Stahlhut, M.; Rutkowski, C.A.; Emini, E.A.; Tata, J.R. P1′ oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. Bioorg. Med. Chem. Lett., 2004, 14(18), 4651-4654.
[49]
Syed, T.; Akhtar, T.; Al-Masoudi, N.A.; Jones, P.G.; Hameed, S. Synthesis, QSAR and anti-HIV activity of new 5-benzylthio-1,3,4-oxadiazoles derived from α-amino acids. J. Enzyme Inhib. Med. Chem., 2011, 26(5), 668-680.
[50]
Zhang, F.; Wang, X.L.; Shi, J.; Wang, S.F.; Yin, Y.; Yang, Y.S.; Zhang, W.M.; Zhu, H.L. Synthesis, molecular modeling and biological evaluation of N-benzylidene-2-((5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)thio)acetohydrazide derivatives as potential anticancer agents. Bioorg. Med. Chem., 2014, 22(1), 468-477.
[51]
Ramazani, A.; Khoobi, M.; Torkaman, A.; Nasrabadi, F.Z.; Forootanfar, H.; Shakibaie, M.; Jafari, M.; Ameri, A.; Emami, S.; Faramarzi, M.A.; Foroumadi, A.; Shafiee, A. One-pot, four-component synthesis of novel cytotoxic agents 1-(5-aryl-1,3,4-oxadiazol-2-yl)-1-(1H-pyrrol-2-yl)methanamines. Eur. J. Med. Chem., 2014, 78, 151-156.
[52]
Sun, J.; Zhu, H.; Yang, Z.M.; Zhu, H.L. Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent. Eur. J. Med. Chem., 2013, 60, 23-28.
[53]
Gurupadaswamy, H.D.; Girish, V.; Kavitha, C.V.; Raghavan, S.C.; Khanum, S.A. Synthesis and evaluation of 2,5-di(4-aryloylaryloxymethyl)-1,3,4-oxadiazoles as anti-cancer agents. Eur. J. Med. Chem., 2013, 63, 536-543.
[54]
Rapolu, S.; Alla, M.; Bommena, V.R.; Murthy, R.; Jain, N.; Bommareddy, V.R.; Bommineni, M.R. Synthesis and biological screening of 5-(alkyl(1H-indol-3-yl))-2-(substituted)-1,3,4-oxadiazoles as antiproliferative and anti-inflammatory agents. Eur. J. Med. Chem., 2013, 66, 91-100.
[55]
Ahsan, M.J.; Rathod, V.P.S.; Singh, M.; Sharma, R.; Jadav, S.S.; Yasmin, S.; Kumar, S.; Kumar, P. Synthesis, anticancer and molecular docking studies of 2-(4-chlorophenyl)-5-aryl-1, 3, 4- oxadiazole analogues. Med. Chem., 2013, 3(4), 294-297.
[56]
Brożewicz, K.; Sławiński, J. 1-(2-Mercaptobenzenesulfonyl)-3-hydroxyguanidines--novel potent antiproliferatives, synthesis and in vitro biological activity. Eur. J. Med. Chem., 2012, 55, 384-394.
[57]
Puthiyapurayil, P.; Poojary, B.; Chikkanna, C.; Buridipad, S.K. Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents. Eur. J. Med. Chem., 2012, 53, 203-210.
[58]
Rashid, M.; Husain, A.; Mishra, R. Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents. Eur. J. Med. Chem., 2012, 54, 855-866.
[59]
Bondock, S.; Adel, S.; Etman, H.A.F.; Badria, F.A. Synthesis and antitumor evaluation of some new 1,3,4-oxadiazole-based heterocycles. Eur. J. Med. Chem., 2012, 48, 192-199.
[60]
Luo, Z.H.; He, S.Y.; Chen, B.Q.; Shi, Y.P.; Liu, Y.M.; Li, C.W.; Wang, Q.S. Synthesis and in vitro antitumor activity of 1,3,4-oxadiazole derivatives based on benzisoselenazolone. Chem. Pharm. Bull. (Tokyo), 2012, 60(7), 887-891.
[61]
Kashaw, S.K.; Kumar, A.; Gupta, A.; Kashaw, V.; Shukla, G.; Mishra, V. Synthesis and anticancer evaluation of some novel 3-[5-(4-substituted)phenyl-1,3,4-oxadiazol-2-yl]-2- Phenylquinazolin-4(3H)-ones. Int. J. Pharma Sci., 2012, 4, 502-506.
[62]
Ren, J.; Wu, L.; Xin, W.Q.; Chen, X.; Hu, K. Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives. Bioorg. Med. Chem. Lett., 2012, 22(14), 4778-4782.
[63]
Gudipati, R.; Anreddy, R.N.R.; Manda, S. Synthesis, characterization and anticancer activity of certain 3-4-(5-mercapto-1, 3, 4-oxadiazol-2-yl)phenyliminoindolin-2-one derivatives. Saudi Pharm. J., 2011, 19, 153-158.
[64]
Zhang, X.M.; Qiu, M.; Sun, J.; Zhang, Y.B.; Yang, Y.S.; Wang, X.L.; Tang, J.F.; Zhu, H.L. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents. Bioorg. Med. Chem., 2011, 19(21), 6518-6524.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Drug Safety
Current Drug Targets
Current Organic Chemistry
Current Organic Synthesis
Mini-Reviews in Organic Chemistry
Letters in Organic Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Related Books
Advances in Organic Synthesis
Frontiers in Drug Design and Discovery
The Synthetic Methods, Structures, and Properties of the Ca-C σ Bond Organocalcium Containing Compounds
Advances in Organic Synthesis
Chemistry of Bipyrazoles: Synthesis and Applications
Frontiers in Cardiovascular Drug Discovery
Advances in Organic Synthesis
Advanced Nanocatalysis for Organic Synthesis and Electroanalysis
Frontiers in Drug Design and Discovery
Advances in Organic Synthesis
Article Metrics
84
2